Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions.

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company ...

Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical ...

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the Danish drugmaker can improve on the data that triggered a jump in ...

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a ...